Axsome Therapeutics (AXSM) Non-Current Assets (2015 - 2026)
Axsome Therapeutics recorded quarterly Non-Current Assets of $102.4 million in Q1 2026, up 1.57% quarter-over-quarter from $100.8 million in Q4 2025, and little changed year-over-year from $102.0 million in Q1 2025.
Axsome Therapeutics' Non-Current Assets history runs 12 years deep, the most recent figure standing at $102.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets changed 0.36% year-over-year to $102.4 million; the TTM figure through Mar 2026 stood at $410.3 million (up 16.23% YoY), while the FY2025 annual figure was $100.8 million, up 20.84% from the prior year.
- Non-Current Assets came in at $102.4 million for Q1 2026 at Axsome Therapeutics, up from $100.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $103.9 million in Q3 2025 to a low of $1.7 million in Q1 2022.
- A 5-year average of $85.2 million and a median of $85.8 million in 2022 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 6675.02% in 2022 and slipped 7.58% in 2024, its largest moves.
- Axsome Therapeutics' Non-Current Assets stood at $85.8 million in 2022, then decreased by 2.17% to $84.0 million in 2023, then dropped by 0.64% to $83.4 million in 2024, then climbed by 20.84% to $100.8 million in 2025, then advanced by 1.57% to $102.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $102.4 million, $100.8 million, and $103.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 102.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.40 Mn |
| Dec 31, 2025 | 100.82 Mn |
| Sep 30, 2025 | 103.91 Mn |
| Jun 30, 2025 | 103.17 Mn |
| Mar 31, 2025 | 102.04 Mn |
| Dec 31, 2024 | 83.43 Mn |
| Sep 30, 2024 | 82.35 Mn |
| Jun 30, 2024 | 85.20 Mn |
| Mar 31, 2024 | 85.24 Mn |
| Dec 31, 2023 | 83.97 Mn |
| Sep 30, 2023 | 89.09 Mn |
| Jun 30, 2023 | 91.95 Mn |
| Mar 31, 2023 | 84.73 Mn |
| Dec 31, 2022 | 85.83 Mn |
| Sep 30, 2022 | 86.57 Mn |
| Jun 30, 2022 | 76.58 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 1.27 Mn |
| Sep 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.61 Mn |
| Mar 31, 2021 | 1.87 Mn |
| Dec 31, 2020 | 2.11 Mn |
| Sep 30, 2020 | 357,120.00 |
| Jun 30, 2020 | 170,297.00 |
| Mar 31, 2020 | 178,093.00 |
| Dec 31, 2019 | 170,498.00 |
| Sep 30, 2019 | 203,523.00 |
| Jun 30, 2019 | 209,716.00 |
| Mar 31, 2019 | 141,909.00 |
| Dec 31, 2018 | 164,177.00 |
| Sep 30, 2018 | 181,395.00 |
| Jun 30, 2018 | 185,991.00 |
| Mar 31, 2018 | 185,598.00 |
| Dec 31, 2017 | 256,023.00 |
| Sep 30, 2017 | 198,635.00 |
| Jun 30, 2017 | 205,815.00 |
| Mar 31, 2017 | 212,807.00 |
| Dec 31, 2016 | 213,551.00 |
| Sep 30, 2016 | 163,551.00 |
| Jun 30, 2016 | 91,290.00 |
| Mar 31, 2016 | 82,692.00 |
| Dec 31, 2015 | 43,278.00 |